Mammalian target of rapamycin (mTOR) inhibitors could be associated with acute nephrotoxicity, according to French researchers. The team describes 4 cancer patients who developed severe acute kidney ...
Industry feedback confirms Rakovina’s approach targeting PTEN-deficient tumours with brain-penetrant ATR/mTOR inhibitors ...
Torqur AG, subsidiary of Swiss Rockets incubator and a clinical-stage company advancing targeted therapies in oncodermatology and oncology, announced the results of the full Phase 2 proof-of-concept ...
EHE treatment is highly individualized, involving surgery, ablation, chemotherapy, and mTOR inhibitors, depending on patient-specific factors. Next-generation sequencing helps identify genetic ...
Researchers at Zhejiang University and Zhongshan Institute for Drug Discovery have discovered phosphatidylinositol 3-kinase δ (PI3Kδ) and mammalian target of rapamycin (mTOR; FRAP1) dual inhibitors ...
Randomized Phase III Study of Gemcitabine and Vinorelbine Versus Gemcitabine, Vinorelbine, and Cisplatin in the Treatment of Advanced Non-Small-Cell Lung Cancer: From the German and Swiss Lung Cancer ...
Groundbreaking studies in mice have sparked a frenzy among longevity enthusiasts—but human trials are still in their infancy. Rapamycin (red) inhibits a protein complex called mTORC1 (mammalian target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results